CG MedTech

At a glance

CG MedTech filed 32 disclosures in the last 12 months, including 4 insider and 3 5% holder. The most recent key filing was on Oct 15: 10%+ shareholder's holding fell by 35,035,560 sh (share consolidation/split).

Revenue for 2025 was ₩47.2B, up 36.4% on 2024. Operating margin was 8.1% against -3.2% a year earlier. Debt was 22% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩28.4B and operating profit of ₩571.6M.

The 2025 annual report lists 118 employees with an average tenure of 6.5 years and average pay of ₩51.1M, #1403 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩36M each on average. It paid no cash dividend for 2025. ㈜시지바이오 and related parties held 40.41% at year end.

From the 2025 annual report

Staff: 118 (74 men, 44 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩6B. Directors and auditors: 5, paid ₩179.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜시지바이오 holds 40.41%; with 0 related parties the group holds 40.41% of common shares at year end (from 34.60% at the start of the year).

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary